Business
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4...
About this update from Canadian Goldcamps Corp
[{"type":"text","content":"CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock\nCAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or the “Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the pricing of its underwritten offering of 5,000,000 shares of its common stock at a price of $6.00 per share. The gross proceeds to the Company from this offering are expected to be $30.0 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about December 19, 2025, subject to satisfaction of customary closing conditions. All of the securities to be sold in the offering are being offered by the Company. CAMP4 currently anticipates using the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, primarily to support continued development activities for its product candidates, as well as general corporate purposes. The financing includes participation from new and existing investors, including a large mutual fund complex, Janus Henderson Investors, Coastlands Capital, EcoR1 Capital, Trails Edge Capital Partners, and Vivo Capital. Leerink Partners is acting as the sole underwriter for the offering. A registration statement on Form S-3 (File No. 333-291432) relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”) and became effective on December 1, 2025. This offering is being made solely by means of a prospectus supplement and accompanying prospectus. A prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC and available on the SEC’s website located at http://www.sec.gov. When available, copies of the prospectus supplement and the accompanying prospectus related to the offering may be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leeri...